{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:03:10Z","timestamp":1790492590525,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02433","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T17:35:32Z","timestamp":1540316132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function"],"prefix":"10.3389","volume":"9","author":[{"given":"Laura","family":"Damele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Montaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Mingari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3324\/haematol.2015.124016","article-title":"Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia","volume":"100","author":"Leoni","year":"2015","journal-title":"Haematologica"},{"key":"B4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1053\/j.seminhematol.2013.09.006","article-title":"Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia","volume":"50","author":"Jabbour","year":"2013","journal-title":"Semin Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/sj.leu.2404690","article-title":"Signal transduction pathways that contribute to myeloid differentiation","volume":"21","author":"Miranda","year":"2007","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3324\/haematol.2016.142877","article-title":"Innovation in hematology","volume":"101","author":"Hehlmann","year":"2016","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1182\/blood-2008-06-164103","article-title":"Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity","volume":"113","author":"Pende","year":"2009","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fimmu.2014.00087","article-title":"Human NK cells: from surface receptors to the therapy of leukemias and solid tumors","volume":"5","author":"Moretta","year":"2014","journal-title":"Front Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2018.04.009","article-title":"nk cells mediate a crucial graft-versus-leukemia effect in haploidentical-HSCT to cure high-risk acute leukemia","volume":"39","author":"Locatelli","year":"2018","journal-title":"Trends Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood-2004-09-3548","article-title":"Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)","volume":"105","author":"Pende","year":"2005","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/cyto.a.22302","article-title":"Human NK cell receptors\/markers: a tool to analyze NK cell development, subsets and function","volume":"83","author":"Montaldo","year":"2013","journal-title":"Cytometry A"},{"key":"B23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.it.2013.07.005","article-title":"Location and cellular stages of natural killer cell development","volume":"34","author":"Yu","year":"2013","journal-title":"Trends Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.smim.2014.01.006","article-title":"Development of human natural killer cells and other innate lymphoid cells","volume":"26","author":"Montaldo","year":"2014","journal-title":"Semin Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ni.3489","article-title":"Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis","volume":"17","author":"Klose","year":"2016","journal-title":"Nat Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1182\/blood-2010-09-303081","article-title":"Development of IL-22-producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue","volume":"117","author":"Tang","year":"2011","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1182\/blood-2011-09-379693","article-title":"Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor","volume":"119","author":"Montaldo","year":"2012","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fimmu.2012.00388","article-title":"Novel immune modulators used in hematology: impact on NK cells","volume":"3","author":"Krieg","year":"2012","journal-title":"Front Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00432-015-2101-4","article-title":"Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia","volume":"142","author":"El Missiry","year":"2016","journal-title":"J Cancer Res Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","article-title":"Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia","volume":"40","author":"Kreutzman","year":"2012","journal-title":"Exp Hematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","article-title":"Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients","volume":"41","author":"La Nasa","year":"2013","journal-title":"Exp Hematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","article-title":"Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients","volume":"43","author":"Caocci","year":"2015","journal-title":"Exp Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1038\/sj.onc.1205398","article-title":"JAKs, STATs and Src kinases in hematopoiesis","volume":"21","author":"Rane","year":"2002","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1158\/1078-0432.CCR-07-5134","article-title":"Regulation of hematopoietic stem cells by the steel factor\/KIT signaling pathway","volume":"14","author":"Kent","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"a002352","DOI":"10.1101\/cshperspect.a002352","article-title":"Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk","volume":"3","author":"Lowell","year":"2011","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/eji.201445326","article-title":"IL-1beta inhibits ILC3 while favoring NK-cell maturation of umbilical cord blood CD34(+) precursors","volume":"45","author":"Ambrosini","year":"2015","journal-title":"Eur J Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1517\/14656566.2012.672974","article-title":"Tyrosine kinase inhibitors in acute and chronic leukemias","volume":"13","author":"Ohanian","year":"2012","journal-title":"Expert Opin Pharmacother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.immuni.2014.11.010","article-title":"Human RORgammat(+)CD34(+) cells are lineage-specified progenitors of group 3 RORgammat(+) innate lymphoid cells","volume":"41","author":"Montaldo","year":"2014","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by gamma(c) family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/ni.2534","article-title":"Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues","volume":"14","author":"Bernink","year":"2013","journal-title":"Nat Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1158\/1078-0432.CCR-06-2981","article-title":"Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects","volume":"13","author":"Johnson","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1182\/blood-2008-02-138701","article-title":"Dasatinib suppresses in vitro natural killer cell cytotoxicity","volume":"111","author":"Blake","year":"2008","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.25233","article-title":"The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity","volume":"127","author":"Salih","year":"2010","journal-title":"Int J Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.immuni.2015.12.007","article-title":"The helix-loop-helix protein ID2 governs NK cell fate by tuning their sensitivity to interleukin-15","volume":"44","author":"Delconte","year":"2016","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/ni.3332","article-title":"Complementarity and redundancy of IL-22-producing innate lymphoid cells","volume":"17","author":"Rankin","year":"2016","journal-title":"Nat Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"14601","DOI":"10.1038\/ncomms14601","article-title":"IL-15 sustains IL-7R-independent ILC2 and ILC3 development","volume":"8","author":"Robinette","year":"2017","journal-title":"Nat Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1084\/jem.20150907","article-title":"Subset- and tissue-defined STAT5 thresholds control homeostasis and function of innate lymphoid cells","volume":"214","author":"Villarino","year":"2017","journal-title":"J Exp Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","article-title":"Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib","volume":"53","author":"Hayashi","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"B53","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1002\/cam4.925","article-title":"Direct effect of dasatinib on signal transduction pathways associated with a rapid mobilization of cytotoxic lymphocytes","volume":"5","author":"Iriyama","year":"2016","journal-title":"Cancer Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1182\/blood-2012-02-412890","article-title":"Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling","volume":"121","author":"Zhang","year":"2013","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02433\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T17:35:33Z","timestamp":1540316133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02433\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":54,"alternative-id":["10.3389\/fimmu.2018.02433"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02433","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"article-number":"2433"}}